Viridian Continues Building Case For Veligrotug In TED

Looking to compete with Amgen’s Tepezza, veligrotug has now met efficacy and safety endpoints in active and chronic patients, while offering less burdensome dosing.

Viridian gets strong data in chronic TED patients (Shutterstock)

More from Clinical Trials

More from Therapy Areas